Increasing unusual option volume: VIXY PCRX
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pacira Pharmaceuticals (PCRX) PT Raised to $46 at Mizuho Securities Following 3Q
November 5, 2018 7:16 AM ESTMizuho Securities analyst Irina Koffler raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $46.00 (from $43.00) while maintaining a Neutral rating following the company's 3Q earnings report. Mizuho Securities raised 2018 Exparel sales to $331.8M (from $321.2M) and 2019 estimates to $396.5M (from $376.8M prior); both above... More
